Pre-registration efficacy study of a novel marker vaccine against classical swine fever on Maternally Derived Antibody negative (MDA-) target animals

R. Lévai, T. Barna, K. Fábián, S. Blome, K. Belák, A. Bálint, F. Koenen, G. Kulcsár, A. Farsang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Classical swine fever (CSF) marker vaccine candidate CP7_E2alf produced under Good Laboratory Practice (GLP) conditions by Pfizer was tested on 40 six-week-old MDA-piglets according to the European Pharmacopoeia (Ph.Eur.) requirements. Single doses of CP7_E2alf were given to 15 piglets orally, while 15 other piglets were intramuscularly vaccinated. Ten additional animals were included as unvaccinated controls. All piglets were oronasally challenged with the highly virulent CSF virus (CSFV) strain "Koslov" 14 days after vaccination.CP7_E2alf administered i.m. provided a complete protection, while p.o. administratrion triggered only partial protection. The level of protection was determined by the development of clinical signs, viraemia and rate of mortality.The vaccine candidate met the criteria of Ph. Eur Monograph 0065, "Swine-fever vaccine (live, prepared in cell cultures), classical" 7th Edition, which claims the efficacy test is invalid if fewer than 50 per cent of the control piglets display typical signs of serious infection of CSF or die, and if fewer than 100 per cent of the control piglets show clinical signs of disease within 21 days following challenge. Fulfilling these validity criteria is a key step in the registration procedure for a vaccine candidate to become openly available.

Original languageEnglish
Pages (from-to)92-99
Number of pages8
JournalBiologicals
Volume43
Issue number2
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

Marker Vaccines
Classical Swine Fever
Vaccines
Antibodies
Animals
Classical swine fever virus
Pharmacopoeias
Viremia
Viruses
Cell culture
Vaccination
Cell Culture Techniques
Mortality
Infection

Keywords

  • Classical swine fever
  • DIVA
  • European pharmacopoeia
  • Histopathology
  • Trial
  • Vaccine

ASJC Scopus subject areas

  • Biotechnology
  • Applied Microbiology and Biotechnology
  • Bioengineering
  • Immunology and Microbiology(all)
  • Pharmacology
  • Medicine(all)

Cite this

Pre-registration efficacy study of a novel marker vaccine against classical swine fever on Maternally Derived Antibody negative (MDA-) target animals. / Lévai, R.; Barna, T.; Fábián, K.; Blome, S.; Belák, K.; Bálint, A.; Koenen, F.; Kulcsár, G.; Farsang, A.

In: Biologicals, Vol. 43, No. 2, 01.03.2015, p. 92-99.

Research output: Contribution to journalArticle

Lévai, R. ; Barna, T. ; Fábián, K. ; Blome, S. ; Belák, K. ; Bálint, A. ; Koenen, F. ; Kulcsár, G. ; Farsang, A. / Pre-registration efficacy study of a novel marker vaccine against classical swine fever on Maternally Derived Antibody negative (MDA-) target animals. In: Biologicals. 2015 ; Vol. 43, No. 2. pp. 92-99.
@article{a882a908d7ab4fbc88eb90a18a1802e2,
title = "Pre-registration efficacy study of a novel marker vaccine against classical swine fever on Maternally Derived Antibody negative (MDA-) target animals",
abstract = "Classical swine fever (CSF) marker vaccine candidate CP7_E2alf produced under Good Laboratory Practice (GLP) conditions by Pfizer was tested on 40 six-week-old MDA-piglets according to the European Pharmacopoeia (Ph.Eur.) requirements. Single doses of CP7_E2alf were given to 15 piglets orally, while 15 other piglets were intramuscularly vaccinated. Ten additional animals were included as unvaccinated controls. All piglets were oronasally challenged with the highly virulent CSF virus (CSFV) strain {"}Koslov{"} 14 days after vaccination.CP7_E2alf administered i.m. provided a complete protection, while p.o. administratrion triggered only partial protection. The level of protection was determined by the development of clinical signs, viraemia and rate of mortality.The vaccine candidate met the criteria of Ph. Eur Monograph 0065, {"}Swine-fever vaccine (live, prepared in cell cultures), classical{"} 7th Edition, which claims the efficacy test is invalid if fewer than 50 per cent of the control piglets display typical signs of serious infection of CSF or die, and if fewer than 100 per cent of the control piglets show clinical signs of disease within 21 days following challenge. Fulfilling these validity criteria is a key step in the registration procedure for a vaccine candidate to become openly available.",
keywords = "Classical swine fever, DIVA, European pharmacopoeia, Histopathology, Trial, Vaccine",
author = "R. L{\'e}vai and T. Barna and K. F{\'a}bi{\'a}n and S. Blome and K. Bel{\'a}k and A. B{\'a}lint and F. Koenen and G. Kulcs{\'a}r and A. Farsang",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.biologicals.2014.12.004",
language = "English",
volume = "43",
pages = "92--99",
journal = "Biologicals",
issn = "1045-1056",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Pre-registration efficacy study of a novel marker vaccine against classical swine fever on Maternally Derived Antibody negative (MDA-) target animals

AU - Lévai, R.

AU - Barna, T.

AU - Fábián, K.

AU - Blome, S.

AU - Belák, K.

AU - Bálint, A.

AU - Koenen, F.

AU - Kulcsár, G.

AU - Farsang, A.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Classical swine fever (CSF) marker vaccine candidate CP7_E2alf produced under Good Laboratory Practice (GLP) conditions by Pfizer was tested on 40 six-week-old MDA-piglets according to the European Pharmacopoeia (Ph.Eur.) requirements. Single doses of CP7_E2alf were given to 15 piglets orally, while 15 other piglets were intramuscularly vaccinated. Ten additional animals were included as unvaccinated controls. All piglets were oronasally challenged with the highly virulent CSF virus (CSFV) strain "Koslov" 14 days after vaccination.CP7_E2alf administered i.m. provided a complete protection, while p.o. administratrion triggered only partial protection. The level of protection was determined by the development of clinical signs, viraemia and rate of mortality.The vaccine candidate met the criteria of Ph. Eur Monograph 0065, "Swine-fever vaccine (live, prepared in cell cultures), classical" 7th Edition, which claims the efficacy test is invalid if fewer than 50 per cent of the control piglets display typical signs of serious infection of CSF or die, and if fewer than 100 per cent of the control piglets show clinical signs of disease within 21 days following challenge. Fulfilling these validity criteria is a key step in the registration procedure for a vaccine candidate to become openly available.

AB - Classical swine fever (CSF) marker vaccine candidate CP7_E2alf produced under Good Laboratory Practice (GLP) conditions by Pfizer was tested on 40 six-week-old MDA-piglets according to the European Pharmacopoeia (Ph.Eur.) requirements. Single doses of CP7_E2alf were given to 15 piglets orally, while 15 other piglets were intramuscularly vaccinated. Ten additional animals were included as unvaccinated controls. All piglets were oronasally challenged with the highly virulent CSF virus (CSFV) strain "Koslov" 14 days after vaccination.CP7_E2alf administered i.m. provided a complete protection, while p.o. administratrion triggered only partial protection. The level of protection was determined by the development of clinical signs, viraemia and rate of mortality.The vaccine candidate met the criteria of Ph. Eur Monograph 0065, "Swine-fever vaccine (live, prepared in cell cultures), classical" 7th Edition, which claims the efficacy test is invalid if fewer than 50 per cent of the control piglets display typical signs of serious infection of CSF or die, and if fewer than 100 per cent of the control piglets show clinical signs of disease within 21 days following challenge. Fulfilling these validity criteria is a key step in the registration procedure for a vaccine candidate to become openly available.

KW - Classical swine fever

KW - DIVA

KW - European pharmacopoeia

KW - Histopathology

KW - Trial

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84924082407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924082407&partnerID=8YFLogxK

U2 - 10.1016/j.biologicals.2014.12.004

DO - 10.1016/j.biologicals.2014.12.004

M3 - Article

C2 - 25637578

AN - SCOPUS:84924082407

VL - 43

SP - 92

EP - 99

JO - Biologicals

JF - Biologicals

SN - 1045-1056

IS - 2

ER -